Holly Sheffield has been leading Trumbull-based CooperSurgical during a period of growth and acquisitions.
CooperSurgical is focused on advancing the health of women, babies and families, and its products include an array of medical devices, such as vacuum-assisted infant delivery devices and amniocentesis needles.
In the past few years, CooperSurgical has announced several major deals, including a $1.6 billion acquisition of California-based Generate Life Sciences, which provides donor egg and sperm for fertility treatments, among other services.
It previously bought U.K.-based Safe Obstetric Systems for around $52 million. It also purchased a California medical device company, Aegea Medical, and Illinois-based Embryo Options, which partners with fertility clinics to help patients manage frozen embryos, eggs and sperm.
Sheffield was named president of CooperSurgical in July 2020, having previously joined its parent, CooperCompanies, as executive vice president and chief strategy officer in 2018.
CooperCompanies has two divisions, CooperSurgical and CooperVision, with the latter focused on vision-related products.
CooperSurgical occupies 267,000 square feet of leased space in Connecticut, including about 77,000 square feet in its Trumbull headquarters at 75 Corporate Drive. It also has 190,000 square feet of distribution, manufacturing and engineering space in two other Trumbull buildings at 95 and 50 Corporate Drive.
Prior to joining the company, Sheffield worked in investment banking for more than two decades, with a focus on medical equipment and technology.
From 2009 to 2018, she was the managing director and global head of medical technology at UBS Securities. She earned an MBA from the Columbia Business School.